Renaissance Technologies
VTVT icon

Renaissance Technologies’s vTv Therapeutics VTVT Stock Holding History

Renaissance Technologies’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-286
Closed -$8K – 4611
2022
Q1 		$8K Buy
+286
New +$8.57K ﹤0.01% 4029
2021
Q1 		– Sell
-1,888
Closed -$140K – 3749
2020
Q4 		$140K Buy
+1,888
New +$145K ﹤0.01% 3215
2020
Q3 		– Sell
-3,319
Closed -$299K – 3725
2020
Q2 		$299K Sell
3,319
-4,063
-55% -$401K ﹤0.01% 3043
2020
Q1 		$564K Buy
7,382
+6,415
+663% +$617K ﹤0.01% 2699
2019
Q4 		$66K Buy
+967
New +$58.7K ﹤0.01% 3365
2018
Q2 		– Sell
-495
Closed -$81K – 3556
2018
Q1 		$81K Sell
495
-880
-64% -$215K ﹤0.01% 3277
2017
Q4 		$331K Buy
1,375
+125
+10% +$28K ﹤0.01% 2998
2017
Q3 		$299K Sell
1,250
-597
-32% -$119K ﹤0.01% 2903
2017
Q2 		$367K Buy
1,847
+252
+16% +$52.5K ﹤0.01% 2844
2017
Q1 		$418K Buy
1,595
+72
+5% +$16.4K ﹤0.01% 2820
2016
Q4 		$294K Buy
1,523
+298
+24% +$68.5K ﹤0.01% 2916
2016
Q3 		$352K Buy
+1,225
New +$295K ﹤0.01% 2917

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.48B AUM 21.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Renaissance Technologies's VTVT Position: Q2 2022 in Review

Renaissance Technologies sold out of vTv Therapeutics (VTVT) in Q2 2022, closing a stake of 286 shares — an estimated $8K sold.

Renaissance Technologies first reported a position in VTVT in Q3 2016 and held it in 12 quarters. The position peaked at $564K in Q1 2020. 23 funds tracked by Wall St. Rank hold VTVT as of Q2 2022.

  • Renaissance Technologies reported no remaining vTv Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Renaissance Technologies sold 286 vTv Therapeutics shares in Q2 2022, an estimated $8K.
  • Renaissance Technologies first reported a position in vTv Therapeutics in Q3 2016 and held it in 12 quarters.
  • Renaissance Technologies's vTv Therapeutics position peaked at $564K in Q1 2020.
  • 23 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.